BARCELONA, SPAIN and SEATTLE, WA--(MARKET WIRE)--Jun 14, 2007 -- Targeted Genetics Corporation (NasdaqCM:TGEN - News) today is reporting data from the dose escalation arm of the ongoing Phase I/II clinical study of tgAAC94 in patients with inflammatory arthritis. Philip J. Mease, M.D., clinical professor at the University of Washington School of Medicine, chief of rheumatology clinical research at the Swedish Medical Center, practicing physician with Seattle Rheumatology Associates and the lead investigator on the trial is presenting the data in a poster session today at the Annual European Congress of Rheumatology EULAR 2007 in Barcelona, Spain (Abstract THU0185). These data also were reported earlier this month at the 10th Annual Meeting of the American Society of Gene Therapy.
